Freenome’s SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review. If approved, the Freenome blood test would compete against Guardant Health’s liquid biopsy, Shield.
The post Liquid Biopsy Firm Freenome Finds a Way to the Public Markets via $330M SPAC Merger appeared first on MedCity News.
